Frontiers in Molecular Neuroscience (Sep 2024)
A novel super-resolution microscopy platform for cutaneous alpha-synuclein detection in Parkinson’s disease
- Ofir Sade,
- Daphna Fischel,
- Daphna Fischel,
- Noa Barak-Broner,
- Shir Halevi,
- Shir Halevi,
- Irit Gottfried,
- Dana Bar-On,
- Dana Bar-On,
- Stefan Sachs,
- Anat Mirelman,
- Anat Mirelman,
- Anat Mirelman,
- Avner Thaler,
- Avner Thaler,
- Aviv Gour,
- Aviv Gour,
- Meir Kestenbaum,
- Meir Kestenbaum,
- Mali Gana Weisz,
- Saar Anis,
- Saar Anis,
- Claudio Soto,
- Melanie Shanie Roitman,
- Shimon Shahar,
- Kathrin Doppler,
- Markus Sauer,
- Nir Giladi,
- Nir Giladi,
- Nir Giladi,
- Nirit Lev,
- Nirit Lev,
- Nirit Lev,
- Roy N. Alcalay,
- Roy N. Alcalay,
- Sharon Hassin-Baer,
- Sharon Hassin-Baer,
- Uri Ashery,
- Uri Ashery
Affiliations
- Ofir Sade
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Daphna Fischel
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Daphna Fischel
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Noa Barak-Broner
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Shir Halevi
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Shir Halevi
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Irit Gottfried
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Dana Bar-On
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Dana Bar-On
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Stefan Sachs
- Department of Biotechnology and Biophysics, Biocenter, University of Würzburg, Würzburg, Germany
- Anat Mirelman
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Anat Mirelman
- Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Anat Mirelman
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Avner Thaler
- Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Avner Thaler
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Aviv Gour
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Aviv Gour
- Department of Neurology, Meir Medical Center, Kfar Saba, Israel
- Meir Kestenbaum
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Meir Kestenbaum
- Department of Neurology, Meir Medical Center, Kfar Saba, Israel
- Mali Gana Weisz
- Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Saar Anis
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Saar Anis
- Department of Neurology, Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan, Israel
- Claudio Soto
- Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, University of Texas Medical School, Houston, TX, United States
- Melanie Shanie Roitman
- Department of Neurology, Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan, Israel
- Shimon Shahar
- Department of Statistics, Exact Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Kathrin Doppler
- 0Department of Neurology, University Hospital Würzburg, Würzburg, Germany
- Markus Sauer
- Department of Biotechnology and Biophysics, Biocenter, University of Würzburg, Würzburg, Germany
- Nir Giladi
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Nir Giladi
- Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Nir Giladi
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Nirit Lev
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Nirit Lev
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Nirit Lev
- Department of Neurology, Meir Medical Center, Kfar Saba, Israel
- Roy N. Alcalay
- Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Roy N. Alcalay
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Sharon Hassin-Baer
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- Sharon Hassin-Baer
- Department of Neurology, Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan, Israel
- Uri Ashery
- School of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel
- Uri Ashery
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- DOI
- https://doi.org/10.3389/fnmol.2024.1431549
- Journal volume & issue
-
Vol. 17
Abstract
Alpha-synuclein (aSyn) aggregates in the central nervous system are the main pathological hallmark of Parkinson’s disease (PD). ASyn aggregates have also been detected in many peripheral tissues, including the skin, thus providing a novel and accessible target tissue for the detection of PD pathology. Still, a well-established validated quantitative biomarker for early diagnosis of PD that also allows for tracking of disease progression remains lacking. The main goal of this research was to characterize aSyn aggregates in skin biopsies as a comparative and quantitative measure for PD pathology. Using direct stochastic optical reconstruction microscopy (dSTORM) and computational tools, we imaged total and phosphorylated-aSyn at the single molecule level in sweat glands and nerve bundles of skin biopsies from healthy controls (HCs) and PD patients. We developed a user-friendly analysis platform that offers a comprehensive toolkit for researchers that combines analysis algorithms and applies a series of cluster analysis algorithms (i.e., DBSCAN and FOCAL) onto dSTORM images. Using this platform, we found a significant decrease in the ratio of the numbers of neuronal marker molecules to phosphorylated-aSyn molecules, suggesting the existence of damaged nerve cells in fibers highly enriched with phosphorylated-aSyn molecules. Furthermore, our analysis found a higher number of aSyn aggregates in PD subjects than in HC subjects, with differences in aggregate size, density, and number of molecules per aggregate. On average, aSyn aggregate radii ranged between 40 and 200 nm and presented an average density of 0.001–0.1 molecules/nm2. Our dSTORM analysis thus highlights the potential of our platform for identifying quantitative characteristics of aSyn distribution in skin biopsies not previously described for PD patients while offering valuable insight into PD pathology by elucidating patient aSyn aggregation status.
Keywords
- alpha-synuclein aggregates
- biomarker
- density-based spatial clustering of applications with noise (DBSCAN)
- direct stochastic optical reconstruction microscopy (dSTORM)
- early diagnosis
- fast optimized cluster algorithm for localizations (FOCAL)